What Is Sagimet Biosciences Inc. - Seri (SGMT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Sagimet Biosciences Inc. - Seri at its current price of $7.99. The composite intrinsic value is estimated at $5.00 (-37.5% average return), with 5 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $10.44 (+30.7%), while ML-RIV — the most conservative — estimates $1.00 (-87.5%). This +118.2% gap reflects genuine analytical uncertainty about Sagimet Biosciences Inc. - Seri's intrinsic worth.
What Do the Models Say About SGMT?
7 of 13 models are currently active for SGMT. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates SGMT's intrinsic value at $2.20, implying -72.4% downside from the current price. See which stocks rank higher →
How Does SGMT Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SGMT ranks #327 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, Sagimet Biosciences Inc. - Seri operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating SGMT should weigh these sector-specific dynamics alongside our model-derived fair values.
Is SGMT a Value Trap?
CirclFi's Value Trap algorithm assigns SGMT a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Sagimet Biosciences Inc. - Seri. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Sagimet Biosciences Inc. - Seri's fundamental quality profile registers 4.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +118.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SGMT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SGMT's 7 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad